Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Trial Profile

Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 May 2017

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Orofacial cancer; Salivary gland cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 13 Jan 2014 New source identified and integrated (Vanderbilt-Ingram Cancer Trials)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top